HeXun Biosciences Income Statement

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021
Period Ending	Jun '24 Jun 30, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	236.41	130.57	49.47	-
Revenue Growth (YoY)	214.00%	163.94%	-	-
Cost of Revenue	19.7	16.84	4.86	-
Gross Profit	216.71	113.73	44.61	-
Selling, General & Admin	37.17	33.14	14.23	5.95
Research & Development	63.28	53.22	39.36	44.71
Operating Expenses	100.45	86.36	53.59	50.66
Operating Income	116.26	27.37	-8.98	-50.66
Interest Expense	-1.57	-1.85	-1.64	-1.57
Interest & Investment Income	3.7	2.79	0.46	0.03
Currency Exchange Gain (Loss)	1.11	0.53	0.02	-
Other Non Operating Income (Expenses)	4.77	4.7	4.93	9.01
EBT Excluding Unusual Items	124.26	33.54	-5.21	-43.19
Gain (Loss) on Sale of Assets	-0.06	-0.05	0.02	0.2
Pretax Income	124.21	33.49	-5.19	-42.99
Net Income	124.21	33.49	-5.19	-42.99
Net Income to Common	124.21	33.49	-5.19	-42.99
Shares Outstanding (Basic)	46	45	38	31
Shares Outstanding (Diluted)	46	45	38	31
Shares Change (YoY)	10.22%	20.81%	22.92%	-
EPS (Basic)	2.70	0.74	-0.14	-1.41
EPS (Diluted)	2.70	0.74	-0.14	-1.41
Free Cash Flow	30.26	22.42	10	-35.5
Free Cash Flow Per Share	0.66	0.49	0.27	-1.16
Gross Margin	91.67%	87.10%	90.18%	-
Operating Margin	49.18%	20.96%	-18.15%	-
Profit Margin	52.54%	25.65%	-10.49%	-
Free Cash Flow Margin	12.80%	17.17%	20.22%	-
EBITDA	133.82	43.12	2.58	-41.87
EBITDA Margin	56.61%	33.03%	5.21%	-
D&A For EBITDA	17.56	15.75	11.56	8.8
EBIT	116.26	27.37	-8.98	-50.66
EBIT Margin	49.18%	20.96%	-18.15%	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.